Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia.
复制标题
起源细胞决定了急性淋巴细胞白血病的攻击性和干细胞数量。
DOI：
10.1038/s41375-018-0130-0
复制
发表时间：
2018-08
期刊：
影响因子：
11.4
通讯作者：
Langenau DM
中科院分区：
文献类型：
--
作者：
Garcia EG;Iyer S;Garcia SP;Loontiens S;Sadreyev RI;Speleman F;Langenau DM
1. Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 2011; 19: 138–52. 2. Craddock C, Quek L, Goardon N, Freeman S, Siddique S, Raghavan M, et al. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 2013; 27: 1028–36. 3. Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, et al. Outcome of azacitidine therapy in acute myeloid leukemia is not improved by concurrent vorinostat therapy but is predicted by a diagnostic molecular signature. Clin Cancer Res 2017. 4. Duncavage EJ, Uy GL, Petti AA, Miller CA, Lee YS, Tandon B, et al. Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy. Blood. 2017; 129: 1397–401. 5. Uy GL, Duncavage EJ, Chang GS, Jacoby MA, Miller CA, Shao J, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. 2017; 31: 872–81. 6. Unnikrishnan A, Papaemmanuil E, Beck D, Deshpande NP, Verma A, Kumari A, et al. Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes. Cell Rep. 2017; 20: 572–85. 7. Welch JS, Petti AA, Miller CA, Fronick CC, O’Laughlin M, Fulton RS, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016; 375: 2023–36. 8. Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, et al. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes. Haematologica. 2017; 102: e216–e218.9. Lubbert M, Daskalakis M, Kunzmann R, Engelhardt M, Guo Y, Wijermans P. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2’-deoxycytidine (decitabine). Leuk Res. 2004; 28: 1267–71. 10. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood. 2011; 116: 3735–42.
登录
查看更多内容
影响因子：
50.3
作者：
Blackburn JS;Liu S;Wilder JL;Dobrinski KP;Lobbardi R;Moore FE;Martinez SA;Chen EY;Lee C;Langenau DM
通讯作者：
Langenau DM
影响因子：
20.3
作者：
Chiang, Mark Y.;Wang, Qing;Pear, Warren S.
通讯作者：
Pear, Warren S.
影响因子：
28.2
作者：
Lobbardi R;Pinder J;Martinez-Pastor B;Theodorou M;Blackburn JS;Abraham BJ;Namiki Y;Mansour M;Abdelfattah NS;Molodtsov A;Alexe G;Toiber D;de Waard M;Jain E;Boukhali M;Lion M;Bhere D;Shah K;Gutierrez A;Stegmaier K;Silverman LB;Sadreyev RI;Asara JM;Oettinger MA;Haas W;Look AT;Young RA;Mostoslavsky R;Dellaire G;Langenau DM
通讯作者：
Langenau DM
影响因子：
45.3
作者：
Goldberg, JM;Silverman, LB;Asselin, BL
通讯作者：
Asselin, BL
DOI：
10.1084/jem.167.2.353
发表时间：
1988-02-01
期刊：
The Journal of experimental medicine
影响因子：
--
作者：
Harris AW;Pinkert CA;Crawford M;Langdon WY;Brinster RL;Adams JM
通讯作者：
Adams JM